A security executive took SureScan EDS from lab stage to $26 million in revenue. He now chairs Liberty Defense.

AstraZeneca reported that its Imfinzi combination therapy reduced the risk of death in a late-stage trial for small cell lung cancer, according to the company. The drug's effectiveness was demonstrated in a specific patient group, which may impact investor sentiment.

Innovent Biologics presented Phase 2 data for IBI354, a HER2-targeted ADC, at the 2026 ESMO Congress. The drug, combined with pertuzumab, showed a 95% objective response rate and favorable safety in first-line HER2-positive breast cancer. Innovent has initiated Phase 3 trials for IBI354 and plans further studies. The company aims to expand its ADC pipeline and improve cancer treatments.

A Phase 3 trial of a combination treatment for advanced lung cancer by Amgen and AstraZeneca showed a 58% reduction in death risk, according to the companies.

POSCO Labor Union announced an indefinite strike starting next month after wage negotiations with management failed. The union demands a 7.1% base pay increase, while the company offered 2.5%. The strike could disrupt production and impact customers, according to the company.

Meta Platforms' AI infrastructure spending is causing financial strain. Free cash flow turned negative in Q3 2026, and future commitments reached $825 billion. This reflects rising pressure on the company's financing power, according to Bloomberg.

Amgen reported that a combination of its drug Imdelltra and AstraZeneca’s Imfinzi reduced death risk by 58% in a late-stage lung cancer trial. Median survival was 21.1 months for the combo group vs. 12.7 months for Imfinzi alone. Amgen's chief medical officer called the data potentially practice-changing. Imdelltra sales grew 115% year-over-year to $288M in Q2.